Payment overview · 2025
General Payments
$2,895.29
125 reported records · 26 companies
Healthcare provider profile · identity verified
Kumar M Ramdas, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MAPLEWOOD, NJ · NPI 1780663898
Verified facts
What the public records show
CMS Open Payments records show Kumar M Ramdas, M.D. received $2,895.29 in general payments during 2025 across 125 reported records.
Madrigal Pharmaceuticals accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Rexulti, Ztlido.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 690 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 690 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Lantus by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ztlido by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $536.94 | 18.6% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $338.36 | 11.7% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $268.87 | 9.3% | 14 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $218.36 | 7.5% | 20 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$165.19 | 5.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $162.11 | 5.6% | 9 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $138.62 | 4.8% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $125.05 | 4.3% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.99 | 4.3% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $123.17 | 4.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $106.97 | 3.7% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $91.84 | 3.2% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $74.15 | 2.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $62.96 | 2.2% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $61.96 | 2.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.65 | 1.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $54.48 | 1.9% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.55 | 1.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.55 | 1.1% | 2 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.96 | 0.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.95 | 0.7% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.64 | 0.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.87 | 0.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.30 | 0.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.16 | 0.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.64 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,895.29 | 125 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $536.94 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $244.55 | 14 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $218.36 | 20 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $171.20 | 9 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $165.19 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $162.11 | 9 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $138.62 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $134.44 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $105.74 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $105.74 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $91.84 | 5 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $86.80 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $81.67 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $74.15 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $62.96 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $61.96 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54.48 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 690 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 286 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 220 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 203 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
286 | 60 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
690 | 90 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
220 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
203 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
196 | 31 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
690 | 90 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
57 | 18 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1485 | 308 |
| Amlodipine Besylate | Amlodipine Besylate | 1298 | 307 |
| Eliquis | Apixaban | 690 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 628 | 150 |
| Losartan Potassium | Losartan Potassium | 614 | 151 |
| Metformin Hcl | Metformin Hcl | 596 | 120 |
| Gabapentin | Gabapentin | 590 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 571 | 146 |
| Furosemide | Furosemide | 538 | 126 |
| Mirtazapine | Mirtazapine | 481 | 73 |
| Divalproex Sodium | Divalproex Sodium | 477 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 76 |
| Celecoxib | Celecoxib | 444 | 151 |
| Lisinopril | Lisinopril | 442 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 429 | 125 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 421 | 111 |
| Clopidogrel | Clopidogrel Bisulfate | 405 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 402 | 86 |
| Omeprazole | Omeprazole | 401 | 93 |
| Carvedilol | Carvedilol | 364 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 358 | 80 |
| Farxiga | Dapagliflozin Propanediol | 286 | 60 |
| Simvastatin | Simvastatin | 275 | 55 |
| Trazodone Hcl | Trazodone Hcl | 268 | 50 |
| Januvia | Sitagliptin Phosphate | 259 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 253 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 248 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 246 | 65 |
| Levetiracetam | Levetiracetam | 243 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 239 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 227 | 45 |
| Donepezil Hcl | Donepezil Hcl | 225 | 45 |
| Jardiance | Empagliflozin | 220 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 213 | 87 |
| Mounjaro | Tirzepatide | 203 | 42 |
| Sertraline Hcl | Sertraline Hcl | 203 | 45 |
| Trulicity | Dulaglutide | 196 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 191 | 73 |
| Vascepa | Icosapent Ethyl | 190 | 39 |
| Meloxicam | Meloxicam | 187 | 65 |
| Spironolactone | Spironolactone | 184 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 182 | 34 |
| Memantine Hcl | Memantine Hcl | 180 | 35 |
| Montelukast Sodium | Montelukast Sodium | 171 | 44 |
| Linzess | Linaclotide | 170 | 53 |
| Famotidine | Famotidine | 160 | 40 |
| Myrbetriq | Mirabegron | 152 | 28 |
| Potassium Chloride | Potassium Chloride | 151 | 39 |
| Valsartan | Valsartan | 150 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 144 | 61 |
| Nifedipine Er | Nifedipine | 144 | 32 |
| Risperidone | Risperidone | 140 | 27 |
| Alendronate Sodium | Alendronate Sodium | 139 | 27 |
| Azithromycin | Azithromycin | 138 | 109 |
| Xarelto | Rivaroxaban | 136 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 127 | 26 |
| Latanoprost | Latanoprost | 122 | 29 |
| Mometasone Furoate | Mometasone Furoate | 122 | 59 |
| Allopurinol | Allopurinol | 112 | 26 |
| Icosapent Ethyl | Icosapent Ethyl | 112 | 34 |
| Buspirone Hcl | Buspirone Hcl | 105 | 16 |
| Ibuprofen | Ibuprofen | 103 | 38 |
| Methylprednisolone | Methylprednisolone | 102 | 57 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 102 | 21 |
| Olanzapine | Olanzapine | 96 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 95 | 34 |
| Tramadol Hcl | Tramadol Hcl | 94 | 34 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 93 | 23 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 89 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 60 |
| Entresto | Sacubitril/Valsartan | 86 | 15 |
| Promethazine Hcl | Promethazine Hcl | 85 | 59 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 83 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 20 |
| Finasteride | Finasteride | 80 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 78 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 20 |
| Aripiprazole | Aripiprazole | 75 | suppressed |
| Lidocaine | Lidocaine | 75 | 21 |
| Tradjenta | Linagliptin | 74 | 13 |
| Clonidine Hcl | Clonidine Hcl | 71 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 68 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 16 |
| Midodrine Hcl | Midodrine Hcl | 66 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | 13 |
| Ketoconazole | Ketoconazole | 64 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 60 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 15 |
| Levofloxacin | Levofloxacin | 58 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 45 |
| Humalog Kwikpen U-100 | Insulin Lispro | 57 | 17 |
| Lactulose | Lactulose | 57 | 23 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 57 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 21 |
| Prednisone | Prednisone | 55 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 46 |
| Fluconazole | Fluconazole | 53 | 30 |
| Albuterol Sulfate | Albuterol Sulfate | 52 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 52 | 13 |
| Colchicine | Colchicine | 52 | 14 |
| Enalapril Maleate | Enalapril Maleate | 51 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 39 |
| Ammonium Lactate | Ammonium Lactate | 49 | 23 |
| Glimepiride | Glimepiride | 48 | 14 |
| Naproxen | Naproxen | 48 | 21 |
| Xiidra | Lifitegrast | 48 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 45 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 44 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Glipizide | Glipizide | 44 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 43 | 43 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | 13 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 22 |
| Ondansetron Odt | Ondansetron | 41 | 11 |
| Alprazolam | Alprazolam | 40 | 14 |
| Amantadine | Amantadine Hcl | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Gemtesa | Vibegron | 39 | suppressed |
| Insulin Lispro | Insulin Lispro | 39 | 19 |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Nystatin | Nystatin | 39 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Haloperidol | Haloperidol | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 38 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 37 | 22 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 32 |
| Timolol Maleate | Timolol Maleate | 36 | suppressed |
| Baclofen | Baclofen | 35 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 35 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Rexulti | Brexpiprazole | 33 | suppressed |
| Clonidine | Clonidine | 32 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 22 |
| Hydrocortisone | Hydrocortisone | 31 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 13 |
| Jentadueto | Linagliptin/Metformin Hcl | 31 | suppressed |
| Folic Acid | Folic Acid | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 28 | 14 |
| Meclizine Hcl | Meclizine Hcl | 28 | 21 |
| Methimazole | Methimazole | 28 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Tivicay | Dolutegravir Sodium | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 20 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 25 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | 12 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Levemir | Insulin Detemir | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | 15 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 20 | suppressed |
| Bystolic | Nebivolol Hcl | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 19 | 17 |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 14 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Nyamyc | Nystatin | 18 | 15 |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ztlido | Lidocaine | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Risperidone Er | Risperidone Microspheres | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 14 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 14 | suppressed |
| Relafen Ds | Nabumetone | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fetroja | Cefiderocol Sulfate Tosylate | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Streptomycin Sulfate | Streptomycin Sulfate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,895.29 · 125 records | Madrigal Pharmaceuticals | AUSTEDO XR, BREZTRI, CAPLYTA, CAPVAXIVE, COBENFY, Dexcom G6 Transmitter, EDARBI, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, HAWKONE, HETLIOZ, JARDIANCE, LEQVIO, MOUNJARO, NUPLAZID, NURTEC ODT, OTEZLA, PURIFIED CORTROPHIN GEL, RECORLEV, REPATHA, REXULTI, REZDIFFRA, TZIELD, VERQUVO, VOQUEZNA, VYNDAQEL, XIFAXAN, ZAVZPRET, ZEPBOUND, ZTLido | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error